De­ci­phera banks a $52M C round for can­cer R&D; Io­n­is adds $50M mile­stone from Bio­gen

→  Waltham, MA-based De­ci­phera Ther­a­peu­tics an­nounced that it has banked a $52 mil­lion C round to keep fu­el­ing its grow­ing pipeline ef­forts, in­clud­ing its lead drug, still in the ear­ly stages of de­vel­op­ment, a pan-KIT and PDGFR in­hibitor dubbed DCC-2618. Viking Glob­al In­vestors, Red­mile Group and Sphera Glob­al Health­care Fund led the round, joined by De­ci­phera’s ex­ist­ing in­vestors in­clud­ing New Leaf Ven­ture Part­ners. Said De­ci­phera CEO Michael Tay­lor: “The pro­ceeds of this fi­nanc­ing will be used to ad­vance de­vel­op­ment of DCC-2618 and DCC-3014 in­to lat­er-stage clin­i­cal tri­als with the goal of de­liv­er­ing new ther­a­pies that ad­dress key re­sis­tance mech­a­nisms to im­prove can­cer treat­ment out­comes.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.